CN108853236A - A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs - Google Patents
A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs Download PDFInfo
- Publication number
- CN108853236A CN108853236A CN201810887263.7A CN201810887263A CN108853236A CN 108853236 A CN108853236 A CN 108853236A CN 201810887263 A CN201810887263 A CN 201810887263A CN 108853236 A CN108853236 A CN 108853236A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine compound
- compound prescription
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of Chinese medicine compound prescription application in preparations of anti-tumor drugs, and according to poidometer, the Chinese medicine compound prescription includes 5-20 parts of honeysuckle, 3-10 parts of oldenlandia diffusa, 1-3 parts of ginseng and 1-15 parts of Prunella vulgaris；The tumour is one of lung cancer, liver cancer, colon cancer, breast cancer and cervical carcinoma or a variety of.The extract of Chinese medicine compound prescription provided by the invention inhibits level in Cytostatic to tumor cell level and tumor growth in vivo, show good antitumous effect, it has a good application prospect in terms of preparing anti-tumor drug, more selections can be provided for clinical cancer therapy.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are related to a kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs.
Background technique
Tumorigenesis is complicated, it has also become seriously threaten the main problem of human health, morbidity and mortality at
The trend risen year by year.China's cancer morbidity is close to world standard, but the death rate is higher than world standard.No matter city or agriculture
Village, tumour are all the major causes of death of Chinese residents.With advancing age, Chinese men and women's disease incidence and the death rate be gradually
Rise.It ranks first in lung cancer in China male's disease incidence, second is occupied in women disease incidence, but male and women die rate top the list
Position.It ranks first in Chinese mammary gland women disease incidence.Therefore prevention is faced with bigger challenge with control.Chinese medicine is motherland's medical use
Carry out the powerful mean of disease preventing and treating, Chinese medicine treats malignant tumour, is either mitigating clinical symptoms, is improving life quality, prevent
Relapse and metastasis extends life cycle, or cooperates with chemicotherapy, and Synergy and attenuation etc. has good effect.
Chinese medicine compound prescription is the main means of traditional Chinese medicine prevention disease.In recent years, compound and its redevelopment to compound,
As the important means of antitumor therapy, by selecting different role mechanism anti-tumor Chinese medicine active principle, synergistic effect makes to treat
Effect is maximized, and the resistance threshold value of tumour cell is reduced, and is laid the foundation for the modernization developmental research of Chinese medicine.
Summary of the invention
The purpose of the present invention is to provide a kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs, the Chinese medicine compound prescriptions pair
Lung cancer, liver cancer, colon cancer, breast cancer and cervical carcinoma all have preferable therapeutic effect.
The present invention is to be achieved through the following technical solutions：
A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs, according to poidometer, the Chinese medicine compound prescription includes gold and silver
5-20 parts of flower, 3-10 parts of oldenlandia diffusa, 1-3 parts of ginseng and 1-15 parts of Prunella vulgaris；The tumour be lung cancer, liver cancer, colon cancer,
One of breast cancer and cervical carcinoma are a variety of.
Preferably, the Chinese medicine compound prescription includes 8~12 parts of honeysuckle, 8~12 parts of oldenlandia diffusa, 1-3 parts of ginseng and summer
1-7 parts of withered grass.
Preferably, the anti-tumor drug is pill, granule, hard capsule, soft capsule, tablet, pill and mouth
Take one of liquid preparation.
It preferably, further include antineoplastic chemotherapy medicine in the anti-tumor drug.
Preferably, the antineoplastic chemotherapy medicine is kinases inhibitor.
Compared with prior art, the invention has the following beneficial technical effects：
The present invention provides a kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs, the Chinese medicine compound prescription includes gold and silver
5-20 parts of flower, 3-10 parts of oldenlandia diffusa, 1-3 parts of ginseng and 1-15 parts of Prunella vulgaris, the Chinese medicine compound prescription is to lung cancer, liver cancer, colon
Cancer, breast cancer and cervical carcinoma have good therapeutic effect.In cell growth inhibition assay, Chinese medicine compound prescription provided by the invention
Extract to 97H, ZR-75-30, MCF-7, LoVo, HepG2, Hep3B, Hela, A549, SMMC-7721 and Bel-7402 ten
Kind cell shows good inhibited proliferation, and majority shows concentration dependent.Anti-tumor experiment in vivo
In, the equal table of Nude Mouse Model that the extract of Chinese medicine compound prescription provided by the invention constructs HepG2, LoVo and ZR-75-30
Reveal good growth inhibition effect.Chinese medicine compound prescription provided by the invention has good application in terms of preparing anti-tumor drug
Prospect can provide more selections for clinical cancer therapy.
Detailed description of the invention
Fig. 1 is inhibited proliferation figure of the oral preparation to tumour cell 97H of the preparation of embodiment 1.
Fig. 2 is inhibited proliferation figure of the oral preparation to tumour cell ZR-75-30 of the preparation of embodiment 1.
Fig. 3 is inhibited proliferation figure of the oral preparation to tumour cell MCF-7 of the preparation of embodiment 1.
Fig. 4 is inhibited proliferation figure of the oral preparation to tumour cell LoVo of the preparation of embodiment 1.
Fig. 5 is inhibited proliferation figure of the oral preparation to tumour cell HepG2 of the preparation of embodiment 1.
Fig. 6 is inhibited proliferation figure of the oral preparation to tumour cell Hep3B of the preparation of embodiment 1.
Fig. 7 is inhibited proliferation figure of the oral preparation to tumour cell Hela of the preparation of embodiment 1.
Fig. 8 is inhibited proliferation figure of the oral preparation to tumour cell A549 of the preparation of embodiment 1.
Fig. 9 is inhibited proliferation figure of the oral preparation to tumour cell SMMC-7721 of the preparation of embodiment 1.
Figure 10 is inhibited proliferation figure of the oral preparation to tumour cell Bel-7402 of the preparation of embodiment 1.
Figure 11 is the growth of oral preparation prepared by embodiment 1 to tumour in the Nude Mouse Model that HepG2 is established
Suppression result figure.
Figure 12 is the growth of oral preparation prepared by embodiment 1 to tumour in the Nude Mouse Model that LoVo is established
Suppression result figure.
Figure 13 is in the Nude Mouse Model that ZR-75-30 is established, and oral preparation prepared by embodiment 1 is to tumour
Growth inhibition result figure.
Specific embodiment
Below with reference to specific embodiment, the present invention is described in further detail, it is described be explanation of the invention and
It is not to limit.
Embodiment 1
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 10 parts of honeysuckle, 10 parts of oldenlandia diffusa, 1 part of ginseng
With 1 part of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 220 parts of 70-75% ethanol waters, filter to obtain filter
Liquid, filter residue use 110 parts of 70-75% ethanol waters to flow back 2 hours again, filtering, merging filtrate, are condensed into medicinal extract, and vacuum is dry
It is dry, it is prepared into oral preparation.
Embodiment 2
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 5 parts of honeysuckle, 8 parts of oldenlandia diffusa, 1 part of ginseng and
1 part of Prunella vulgaris.
It is mixed after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours, filtered to get filtrate with 180 parts of water；Filter residue uses 90 parts again
70-75% ethanol water flows back 2 hours, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral preparation.
Embodiment 3
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 13 parts of honeysuckle, 5 parts of oldenlandia diffusa, ginseng 1.5
Part and 1 part of Prunella vulgaris.
It is mixed after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours, filtered to get filtrate with 180 parts of water；Filter residue uses 90 parts again
70-75% ethanol water flows back 2 hours, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral preparation.
Embodiment 4
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 5 parts of honeysuckle, 10 parts of oldenlandia diffusa, 2 parts of ginseng
With 10 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 230 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of 70-75% ethanol waters to flow back 2 hours again, filtering, merging filtrate, is condensed into medicinal extract, and vacuum is dry
It is dry, it is prepared into oral preparation.
Embodiment 5
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 10 parts of honeysuckle, 10 parts of oldenlandia diffusa, 1 part of ginseng
With 6.7 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 230 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 100 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 6
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 20 parts of honeysuckle, 5 parts of oldenlandia diffusa, 3 parts of ginseng
With 10 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 350 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 150 parts of 70-75% ethanol waters to flow back 2 hours again, filtering, merging filtrate, is condensed into medicinal extract, and vacuum is dry
It is dry, it is prepared into oral preparation.
Embodiment 7
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 10 parts of honeysuckle, 3 parts of oldenlandia diffusa, 2 parts of ginseng
With 15 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 280 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of 70-75% ethanol waters to flow back 2 hours again, filtering, merging filtrate, is condensed into medicinal extract, and vacuum is dry
It is dry, it is prepared into oral preparation.
Embodiment 8
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 15 parts of honeysuckle, 5 parts of oldenlandia diffusa, 2 parts of ginseng
With 13 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 300 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 150 parts of 70-75% ethanol waters to flow back 2 hours again, filtering, merging filtrate, is condensed into medicinal extract, and vacuum is dry
It is dry, it is prepared into oral preparation.
Embodiment 9
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 15 parts of honeysuckle, 10 parts of oldenlandia diffusa, 3 parts of ginseng
With 1.5 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 280 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 10
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 10 parts of honeysuckle, 3 parts of oldenlandia diffusa, 1 part of ginseng
With 9 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 220 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 110 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 11
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 8 parts of honeysuckle, 12 parts of oldenlandia diffusa, 2 parts of ginseng
With 7 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 280 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 12
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 12 parts of honeysuckle, 12 parts of oldenlandia diffusa, 3 parts of ginseng
With 1 part of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 280 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 13
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 12 parts of honeysuckle, 8 parts of oldenlandia diffusa, 1 part of ginseng
With 6.7 parts of Prunella vulgaris.
It mixes after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours with 280 parts of 70-75% ethanol waters, filter to obtain filter
Liquid；Filter residue uses 140 parts of water to flow back 2 hours again, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral system
Agent.
Embodiment 14
A kind of antitumor Chinese medicine compound prescription, according to poidometer, including 8 parts of honeysuckle, 8 parts of oldenlandia diffusa, 3 parts of ginseng and
3 parts of Prunella vulgaris.
It is mixed after above-mentioned medicinal material is crushed respectively, is flowed back 2 hours, filtered to get filtrate with 220 parts of water；Filter residue uses 110 again
Part water flows back 2 hours, and filtering, merging filtrate is condensed into medicinal extract, is dried in vacuo, is prepared into oral preparation.
Wherein, according to common sense, it is appropriate that those skilled in the art combine after obtaining merging filtrate, after filtrate being concentrated
Auxiliary material, be prepared into pill, granule, hard capsule, soft capsule, tablet, pill, oral liquid etc. routinely make
Agent.
Wherein, the combination therapy of a variety of drugs, those skilled in the art are generallyd use in existing clinical therapy of tumor strategy
Member, which can according to need, is prepared into compound medicine for compound and antineoplastic chemotherapy medicine of the invention, to reach more preferable geological measuring effect
Fruit and convenient drug combination.In common antineoplastic chemotherapy medicine, preferably select with better choice and targeting
Kinases inhibitor.
Embodiment 15：The proliferation function of 1 gained oral preparation (ZYFF) of embodiment inhibition tumour cell
1. instrument and material
SW-CJ-1F type superclean bench (safe and sound air technique Co., Ltd of Suzhou City)；Ti-U type inverted microscope
(Nikon)；MAC 15AC type carbon dioxide constant incubator (SANYO)；80-2 type desktop electric centrifuge (Shanghai City analyzer
Tool factory)；GH water isolation type constant incubator (Beijing Yongxing Ke Wei Instrument Ltd.)；Pipettor (Eppendorf)；UPT-
IV-5T ultrapure water draft machine (the ultrapure Science and Technology Ltd. in Chengdu)；(the upper positive Medical Instruments of sea light is limited for BP211D electronic balance
Company)；Cell counting board (Shanghai refinement biochemical reagents Co., Ltd)；Culture plate (Costar).
2. experimental method
By the method for MTT experiment, detection test Chinese traditional compound medicine is to 10 kinds of tumour cells 97H, ZR-75-30, MCF-
7, the inhibiting effect of LoVo, HepG2, Hep3B, Hela, A549, SMMC-7721 and Bel-7402.The exponential rise period will be in
Cell, digested with pancreatin, dispel into single cell suspension, count, be inoculated into 96 well culture plates.It cultivates in the incubator for 24 hours,
After cell is adherent, the testing drug of various concentration is added, terminates culture after acting on 48h respectively, 20 μ l MTT are added in every hole
(5mg/ml), 37 DEG C are protected from light incubation 4h.Then liquid in each hole is discarded, 150 μ l DMSO is added, shaken 15min, make to tie
Brilliant object sufficiently dissolves, and cell OD value is measured under microplate reader 490nm wavelength.
3. experimental result
ZYFF all has good inhibiting effect (Fig. 1-10) on 10 kinds of tumour cells, in 0.04mg/mL, 0.2mg/
There is preferable dose-effect relationship in 4 concentration ranges such as mL, 1mg/mL and 5mg/mL.
Embodiment 16：1 gained oral preparation (ZYFF) of embodiment inhibits the experiment of tumour cell transplanted tumor in nude mice
1. instrument and material
Syklofosfamid ampoule (Hengrui Medicine Co., Ltd., Jiangsu Prov.).
Ti-U type inverted microscope (Nikon)；80-2 type desktop electric centrifuge (analyzes instrument factory in Shanghai City)；Pipettor
(Eppendorf)；UPT-IV-5T ultrapure water draft machine (the ultrapure Science and Technology Ltd. in Chengdu)；BP211D electronic balance (Shanghai
Guang Zheng Medical Instruments Co., Ltd)；Cell counting board (Shanghai refinement biochemical reagents Co., Ltd)；Disposable syringe (Jiangxi
City Kingsoft Medical Devices Co., Ltd.)；Vernier caliper (Wuxi City tin measuring tool Co., Ltd)；Operating scissors (Shanghai City Medical treatment device
Tool Co., Ltd)；Ultra low temperature freezer (Haier Group of Qingdao City)；Cell factory culture systems (NUNC).
Nude mice 4-6 week old, Xi'an Communications University's Experimental Animal Center provide, freely absorb food and water, be incubated at 22-24
DEG C, 50%-70%, the clean animal house of 12h-12h fight-darkness cycle.
2. experimental method
Tumour cell LoVo, HepG2 and ZR-75-30 in increased logarithmic phase are diluted to carefully with sterile saline
Born of the same parents' concentration is 2 × 107A/ml.By cell suspension inoculation in mouse right axillary nest subcutaneous position, every 0.2ml.Inoculation one week or so
After tumour is formed, the major diameter (L) and minor axis (W) of vernier caliper measurement tumour are used every three days, according to formula V (mm3)=(L ×
W2)/2, the volume of tumour is calculated.When gross tumor volume reaches 0.1cm3When, mouse is grouped at random, gastric infusion simultaneously records body
Weight, gross tumor volume are primary per measurement every other day.After stomach-filling 14d, cervical dislocation puts to death mouse, removes tumor tissues and weighs.According to
Formula calculates：Tumour inhibiting rate (%)=(control group knurl weight-administration group knurl weight)/control group knurl weight × 100%.
3. experimental result
As figs 11-13, when ZYFF administration concentration is 75mg/kg, 150mg/kg, 300mg/kg, in 3 kinds of nude mices
The effect for inhibiting tumour is showed on Transplanted tumor model.For administration group compared with negative control group, administration group reduces transplanted tumor in nude mice
While volume and knurl weight, nude mice weight rises, and does not reduce, illustrates that ZYFF is not apparent to the physiological status of mouse
It influences, does not show the toxic side effect to experimental animal.
Claims (5)
1. a kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs, which is characterized in that according to poidometer, the Chinese medicine compound prescription
Including 5-20 parts of honeysuckle, 3-10 parts of oldenlandia diffusa, 1-3 parts of ginseng and 1-15 parts of Prunella vulgaris；The tumour is lung cancer, liver
One of cancer, colon cancer, breast cancer and cervical carcinoma are a variety of.
2. Chinese medicine compound prescription application in preparation of anti-tumor drugs as described in claim 1, which is characterized in that the Chinese medicine is multiple
Side includes 8~12 parts of honeysuckle, 8~12 parts of oldenlandia diffusa, 1-3 parts of ginseng and 1-7 parts of Prunella vulgaris.
3. Chinese medicine compound prescription application in preparation of anti-tumor drugs as described in claim 1, which is characterized in that described antitumor
Drug is one of pill, granule, hard capsule, soft capsule, tablet, pill and oral liquid.
4. Chinese medicine compound prescription application in preparation of anti-tumor drugs as described in claim 1, which is characterized in that described antitumor
It further include antineoplastic chemotherapy medicine in drug.
5. Chinese medicine compound prescription application in preparation of anti-tumor drugs as claimed in claim 4, which is characterized in that described antitumor
Chemotherapeutics is kinases inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018101672131 | 2018-02-28 | ||
| CN201810167213.1A CN108143796A (en) | 2018-02-28 | 2018-02-28 | A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108853236A true CN108853236A (en) | 2018-11-23 |
Family
ID=62456047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810167213.1A Pending CN108143796A (en) | 2018-02-28 | 2018-02-28 | A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs |
| CN201810887263.7A Pending CN108853236A (en) | 2018-02-28 | 2018-08-06 | A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810167213.1A Pending CN108143796A (en) | 2018-02-28 | 2018-02-28 | A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108143796A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179875A (en) * | 2019-04-13 | 2019-08-30 | 四川代代相传生物科技有限公司 | A kind of Chinese medicine composition of prophylactic treatment liver human primary gastrointestinal cancers |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683499A (en) * | 2008-09-24 | 2010-03-31 | 王孙勇 | Cancer curing capsule |
| CN104383390A (en) * | 2014-10-30 | 2015-03-04 | 宿州学院 | Chinese traditional medicine preparation for treating lung cancer |
| CN104706729A (en) * | 2015-02-28 | 2015-06-17 | 西安交通大学 | Traditional Chinese medicine extract with antitumor effect as well as extraction method and application thereof |
| CN105434435A (en) * | 2015-12-07 | 2016-03-30 | 西安交通大学 | Medicinal composition with synergic anti-tumor effect and application thereof |
-
2018
- 2018-02-28 CN CN201810167213.1A patent/CN108143796A/en active Pending
- 2018-08-06 CN CN201810887263.7A patent/CN108853236A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683499A (en) * | 2008-09-24 | 2010-03-31 | 王孙勇 | Cancer curing capsule |
| CN104383390A (en) * | 2014-10-30 | 2015-03-04 | 宿州学院 | Chinese traditional medicine preparation for treating lung cancer |
| CN104706729A (en) * | 2015-02-28 | 2015-06-17 | 西安交通大学 | Traditional Chinese medicine extract with antitumor effect as well as extraction method and application thereof |
| CN105434435A (en) * | 2015-12-07 | 2016-03-30 | 西安交通大学 | Medicinal composition with synergic anti-tumor effect and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张崇武: "白花蛇舌草治疗中线恶性网织细胞增生症等有效", 《中医杂志》 * |
| 徐光星: "何任教授治疗原发性肝癌学术思想探究", 《中华中医药杂志》 * |
| 胡熙明: "《中国中医秘方大全 妇产科分卷.儿科分卷.肿瘤科分卷 下卷》", 31 January 1996, 文汇出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108143796A (en) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity | |
| JP5580409B2 (en) | Composition for injection for topical administration for anti-cancer treatment containing hydroxychloroquine | |
| CN103371991A (en) | Application of dimethyldiguanide in preparation of medicaments for preventing or treating hepatocellular carcinoma | |
| CN109908143A (en) | New application of Theo Buddhist nun sieve in preparation treatment acute myeloid leukemia drug | |
| CN107550900A (en) | Application of the Oridonin in terms of protein kinase B inhibitor is prepared | |
| CN108434455A (en) | Application of the MTHFD2 specific inhibitors in terms of preventing colorectal cancer | |
| CN109091480A (en) | Cancer composition 10-hydroxycamptothecine and gram azoles are for Buddhist nun's treatment lung cancer and purposes | |
| CN106265722A (en) | The application in prevention and control of cancer of the ozone carburetion | |
| CN108853236A (en) | A kind of Chinese medicine compound prescription application in preparation of anti-tumor drugs | |
| CN105434435B (en) | It is a kind of to have effects that the pharmaceutical composition of synergistic antitumor and its application | |
| CN101991579A (en) | Use of ursolic acid as colon tumor resistant medicament | |
| CN101125140B (en) | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect | |
| CN100443080C (en) | Medicinal composition for preventing and treating cancer diseases | |
| TWI797426B (en) | Use of chiauranib in treating small cell lung cancer | |
| CN100553629C (en) | The application of paeonol in preparation anti esophageal cancer medicine | |
| CN109106716A (en) | The purposes of the combination of onocerin and fluorouracil in the preparation of antitumor drugs | |
| CN106265619A (en) | DFMO or DFMO and Rhizoma Zingiberis Recens extract application in the medicine of the preparation esophageal carcinoma and the prevention of hepatocarcinoma and clinical treatment | |
| CN107320472A (en) | A kind of pharmaceutical composition and its application for being used to treat liver cancer | |
| CN103483187B (en) | 4-ethyoxyl-2-hydroxyl-6-methyl benzoic acid and Pharmaceutical composition thereof and application | |
| CN100546621C (en) | A kind of new purposes of known drug | |
| Yin et al. | Expression of phosphatase and tensin homolog deleted on chromosome ten in liver of athymic mice with hepatocellular carcinoma and the effect of Fuzheng Jiedu Decoction | |
| CN101884648A (en) | Realgar for treating stomach cancer | |
| CN105663116B (en) | A kind of pharmaceutical composition for being used to treat neuroblastoma | |
| Tang et al. | Effect of dioscorea pills on immunity of mice receiving chemotherapy for ovarian cancer | |
| CN103127510A (en) | Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181123 |